version 14·0 Search Results


93
Glencoe Software Inc bio formats tool bfconvert version 6 14 0
Bio Formats Tool Bfconvert Version 6 14 0, supplied by Glencoe Software Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bio formats tool bfconvert version 6 14 0/product/Glencoe Software Inc
Average 93 stars, based on 1 article reviews
bio formats tool bfconvert version 6 14 0 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

99
SYSTAT sigmaplot v14
Sigmaplot V14, supplied by SYSTAT, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot v14/product/SYSTAT
Average 99 stars, based on 1 article reviews
sigmaplot v14 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

99
STATA Corporation stata mp software version 14 0
Stata Mp Software Version 14 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stata mp software version 14 0/product/STATA Corporation
Average 99 stars, based on 1 article reviews
stata mp software version 14 0 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

90
Mcs GmbH multi channel analyzer version 2.14.0.19346
Multi Channel Analyzer Version 2.14.0.19346, supplied by Mcs GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multi channel analyzer version 2.14.0.19346/product/Mcs GmbH
Average 90 stars, based on 1 article reviews
multi channel analyzer version 2.14.0.19346 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Broad Institute Inc gene set enrichment analysis version 2.0.14
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Gene Set Enrichment Analysis Version 2.0.14, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene set enrichment analysis version 2.0.14/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
gene set enrichment analysis version 2.0.14 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SPSS Inc version 14.0
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Version 14.0, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 14.0/product/SPSS Inc
Average 90 stars, based on 1 article reviews
version 14.0 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SPSS Inc windows, version 14.0
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Windows, Version 14.0, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/windows, version 14.0/product/SPSS Inc
Average 90 stars, based on 1 article reviews
windows, version 14.0 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SPSS Inc version 14.0 k software
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Version 14.0 K Software, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 14.0 k software/product/SPSS Inc
Average 90 stars, based on 1 article reviews
version 14.0 k software - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SAS institute jmp version 14.0 for windows
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Jmp Version 14.0 For Windows, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jmp version 14.0 for windows/product/SAS institute
Average 90 stars, based on 1 article reviews
jmp version 14.0 for windows - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SAS institute jms pro version 14.2.0
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Jms Pro Version 14.2.0, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jms pro version 14.2.0/product/SAS institute
Average 90 stars, based on 1 article reviews
jms pro version 14.2.0 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SPSS Inc versions 14.0 15.0 software
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Versions 14.0 15.0 Software, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/versions 14.0 15.0 software/product/SPSS Inc
Average 90 stars, based on 1 article reviews
versions 14.0 15.0 software - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
SPSS Inc social version 14.02
ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis <t>(GSEA)</t> to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).
Social Version 14.02, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/social version 14.02/product/SPSS Inc
Average 90 stars, based on 1 article reviews
social version 14.02 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis (GSEA) to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).

Journal: European Urology

Article Title: The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer

doi: 10.1016/j.eururo.2015.10.042

Figure Lengend Snippet: ESR1 is upregulated in response to degarelix treatment. (A) Dot plots to show mRNA expression levels of ESR1 in untreated and degarelix-treated prostate cancer (PCa) samples by expression array. (Bi) Using the Gene Set Enrichment Analysis (GSEA) to examine the distribution of known genes with the ESR1 binding motif, shown within their promoter regions, we found that these genes were enriched among genes that degarelix treatment upregulated when they were ranked by their statistical significance. The ESR1 binding motif analysed was described previously . (Bii) This ESR1 binding motif closely matches the validated, experimentally derived ESR1 binding motif shown here. (C) GSEA demonstrates enrichment of factors known to be involved with ESR1 signalling (from the National Cancer Institute BIOCARTA curated database) among genes differentially expressed in response to degarelix ranked by statistical significance. For this analysis, the degree to which the genes were enriched is defined by the running sum statistic called the normalised enrichment score , which was 2.036 (false discovery rate q -value of 0.027; p = 0.024). (D) Representative images of PCa samples stained by immunohistochemistry (IHC) for ESR1 in untreated and degarelix-treated patients with intense nuclear staining seen in the malignant epithelia of the treated but not the untreated samples. Scale bars = 250 μm. (E) IHC ESR1 staining was increased in treated (+) compared with untreated (−) PCa samples in malignant epithelia but not cancer-associated stroma or benign epithelia (samples in triplicate; sample sizes [ n ] indicate the number of subjects [20 or 27] times 3 minus missing or damaged samples on the human tissue microarray; staining intensity 0 [none] to 3 [strong]). Mean intensities from replicate samples for each patient were used to calculate statistical significance when comparing treated and untreated groups (Mann-Whitney test). (F) Graph shows correlation between intensity of staining by IHC for ESR1 and Ki-67. Spearman's ρ correlation coefficient of 0.338 ( p = 0.041).

Article Snippet: We used Gene Set Enrichment Analysis (GSEA) version 2.0.14 (The Broad Institute, Cambridge, MA, USA).

Techniques: Expressing, Binding Assay, Derivative Assay, Staining, Immunohistochemistry, Microarray, MANN-WHITNEY